Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9426432 | 0.87 | GABRA1 (0.69) | KDM4EGABRA1GABRB2HTT | |
| SCHEMBL17337999 | 0.86 | GABRA1 (0.68) | KDM4EGABRA1GABRB2HTT | |
| SCHEMBL17337966 | 0.85 | GABRA1 (0.67) | KDM4EGABRA1GABRB2HTT | |
| SCHEMBL17337963 | 0.84 | KDM4E (0.56) | KDM4EGABRA1GABRB2HTTGABRB1 | |
| SCHEMBL3812183 | 0.82 | HTT (0.52) | KDM4EGABRA1GABRB2HTT | |
| SCHEMBL396402 | 0.81 | GABRA1 (0.73) | KDM4EGABRA1GABRB2HTTPOLB | |
| SCHEMBL3812486 | 0.80 | GABRA1 (0.53) | KDM4EGABRA1GABRB2HTT | |
| SCHEMBL13718281 | 0.79 | GABRA1 (0.52) | KDM4EGABRA1GABRB2HTT | |
| SCHEMBL4451135 | 0.78 | GABRA1 (0.75) | KDM4EGABRA1GABRB2HTTGABRB1 | |
| SCHEMBL4650044 | 0.78 | GABRA1 (0.70) | KDM4EGABRA1GABRB2HTTGABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | KDM4E 3897/4885GABRA1 3341/4885GABRB2 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.